Atacicept in Subjects With IgA Nephropathy
Trial details
- Registry ID
- NCT04716231
- Drugs studied
- Atacicept
TrialRedline tracks 5 clinical trials sponsored by Vera Therapeutics, Inc.: 1 Phase 3, 4 Phase 2.
Company identity checked against sources
| Trial | Drugs studied | Status | Primary completion |
|---|---|---|---|
| Atacicept in Subjects With IgA NephropathyNCT04716231 | Atacicept | Active not recruiting | 2025-05-15Actual |
| Trial | Drugs studied | Status | Primary completion |
|---|---|---|---|
| Atacicept in Multiple Glomerular DiseasesNCT06983028 | Atacicept | Recruiting | 2027-11Estimated |
| A Rollover Study to Evaluate the Long-Term Safety and Efficacy of AtaciceptNCT06674577 | Atacicept 150 mg | Enrolling by invitation | 2031-05-21Estimated |
| Monthly Dosing of Atacicept in IgANNCT07020923 | Atacicept | Active not recruiting | 2026-09-22Actual |
| A Safety, Pharmacokinetics and Efficacy Study of MAU868 for the Treatment of BK Viremia in Kidney Transplant RecipientsNCT04294472 | MAU868 | Completed | 2022-02-10Actual |
Names as written in the registry records.
NCT07020923 · Vera Therapeutics, Inc.
Before: Estimated. After: Actual.
Before: Sep 2026. After: 22 Sep 2026.
NCT04716231 · Vera Therapeutics, Inc.
Text changed; whether the study measures changed has not been verified. Saved text may be shortened.
Before: Measure: Change from baseline in urine protein to creatinine ratio (UPCR) Description: UPCR based on 24 hour urine collection Time frame: 36 Weeks. After: Measure: Percentage Change From Baseline in Urine Protein to Creatinine Ratio (UPCR) Description: Percentage reduction in UPCR was obtained from geometric mean ratios. The natural log-transformed ratio of UPCR to its baseline value was analyzed using a Mixed Model for Repeated Measures (MMRM), adjusted by baseline variables specified in the Statistical Analysis Plan (SAP), including data from baseline up to Week 36 during the Double-Blind period. Time frame: 36 Weeks.
Before: Estimated. After: Actual.
Before: 376 participants (planned). After: 428 participants (actual).
NCT06983028 · Vera Therapeutics, Inc.
Before: 200 participants (planned). After: 250 participants (planned).
NCT06674577 · Vera Therapeutics, Inc.
Before: 476 participants (planned). After: 750 participants (planned).
Before: 31 May 2028. After: 21 May 2031.
NCT07020923 · Vera Therapeutics, Inc.
Before: Recruiting. After: Active not recruiting.